ES2614113T3 - Uso de tricloro (dioxietilen-O,O’) telurato de amonio (AS101) para la inhibición de la enzima convertidora de interleucina-1 beta - Google Patents

Uso de tricloro (dioxietilen-O,O’) telurato de amonio (AS101) para la inhibición de la enzima convertidora de interleucina-1 beta Download PDF

Info

Publication number
ES2614113T3
ES2614113T3 ES05779639.3T ES05779639T ES2614113T3 ES 2614113 T3 ES2614113 T3 ES 2614113T3 ES 05779639 T ES05779639 T ES 05779639T ES 2614113 T3 ES2614113 T3 ES 2614113T3
Authority
ES
Spain
Prior art keywords
oil
inhibition
dioxyethylene
interleukin
trichloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05779639.3T
Other languages
English (en)
Spanish (es)
Inventor
Michael Albeck
Benjamin Sredni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomas Ltd
Original Assignee
Biomas Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomas Ltd filed Critical Biomas Ltd
Application granted granted Critical
Publication of ES2614113T3 publication Critical patent/ES2614113T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C395/00—Compounds containing tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F11/00—Compounds containing elements of Groups 6 or 16 of the Periodic Table
    • C07F11/005—Compounds containing elements of Groups 6 or 16 of the Periodic Table compounds without a metal-carbon linkage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
ES05779639.3T 2004-09-17 2005-09-15 Uso de tricloro (dioxietilen-O,O’) telurato de amonio (AS101) para la inhibición de la enzima convertidora de interleucina-1 beta Expired - Lifetime ES2614113T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61066004P 2004-09-17 2004-09-17
US610660P 2004-09-17
PCT/IL2005/000990 WO2006030438A2 (en) 2004-09-17 2005-09-15 Use of tellurium compounds for inhibition of interleukin-converting enzyme

Publications (1)

Publication Number Publication Date
ES2614113T3 true ES2614113T3 (es) 2017-05-29

Family

ID=35985262

Family Applications (2)

Application Number Title Priority Date Filing Date
ES05779419T Expired - Lifetime ES2312012T3 (es) 2004-09-17 2005-09-15 Nuevos compuestos de telurio y su uso como inmunomodulares.
ES05779639.3T Expired - Lifetime ES2614113T3 (es) 2004-09-17 2005-09-15 Uso de tricloro (dioxietilen-O,O’) telurato de amonio (AS101) para la inhibición de la enzima convertidora de interleucina-1 beta

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES05779419T Expired - Lifetime ES2312012T3 (es) 2004-09-17 2005-09-15 Nuevos compuestos de telurio y su uso como inmunomodulares.

Country Status (10)

Country Link
US (5) US7709524B2 (enExample)
EP (3) EP1796660B1 (enExample)
JP (1) JP2008513439A (enExample)
AT (1) ATE402709T1 (enExample)
AU (1) AU2005283719A1 (enExample)
CA (3) CA2580643C (enExample)
DE (1) DE602005008622D1 (enExample)
ES (2) ES2312012T3 (enExample)
PT (1) PT1796660T (enExample)
WO (3) WO2006030437A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2550459C (en) 2003-12-18 2009-12-15 Biomas, Ltd. Tellurium derivatives for prevention and treatment of neurodegenerative processes
CA2553803C (en) * 2004-01-22 2015-08-18 Benjamin Sredni Therapeutic methods and pharmaceutical compositions for treating warts with tellurium compounds
CA2580643C (en) * 2004-09-17 2018-06-12 Biomas, Ltd. Use of tellurium compounds for inhibition of interleukin-converting enzyme
US20080260770A1 (en) * 2004-09-17 2008-10-23 Biomas Ltd. Use of Tellurium Compounds as Adjuvants
EP1841597A4 (en) 2005-01-11 2010-01-27 Jemtex Ink Jet Printing Ltd INK JET PRINTER AND CONTROL METHOD THEREFOR
CA2619073A1 (en) * 2005-09-15 2007-03-22 Biomas Ltd. Use of tellurium compounds for protection from ultra-violet radiation
JP5028480B2 (ja) * 2006-06-01 2012-09-19 ノベラ ファルマ ソシエダッド リミターダ 手足症候群の治療のためのアロプリノールの使用
EP1862166A1 (en) * 2006-06-01 2007-12-05 Yolanda Rodemer Use of allopurinol for the treatment of palmar plantar erythrodysesthesia
EP2076274A4 (en) * 2006-09-11 2010-08-04 Biomas Ltd TOPICAL FORMULATIONS OF COMPOUNDS CONTAINING TELLURE
WO2009066301A2 (en) * 2007-11-23 2009-05-28 Biomas Ltd. Methods and compositions for treating pox virus with tellurium-containing compounds
EP2826371B1 (en) 2007-11-23 2019-01-02 Feramda Ltd. Methods and compositions for inhibiting integrins using tellurium-containing compounds
US20120035260A1 (en) * 2009-01-08 2012-02-09 Biomas Ltd. Tellurium-containing compounds for affecting female's reproductive system following chemotherapy and/or radiotherapy
WO2010079488A1 (en) * 2009-01-08 2010-07-15 Biomas Ltd. Tellurium-containing compounds for affecting male's fertility following chemotherapy and/or radiotherapy
EP2246057A1 (en) 2009-04-29 2010-11-03 Nobera Pharma, S.L. Use of allopurinol for the treatment of hand foot skin reaction
WO2010146547A1 (en) * 2009-06-16 2010-12-23 Biomas Ltd. Tellurium-containing compounds for facilitating transplantation
JP2013506686A (ja) 2009-09-30 2013-02-28 プレジデント アンド フェロウズ オブ ハーバード カレッジ オートファジー阻害遺伝子産物の変調によりオートファジーを変調する方法
WO2012065065A1 (en) * 2010-11-12 2012-05-18 Follica, Inc. Methods and compositions for modulating hair growth, wound healing and scar revision
JP2014500275A (ja) 2010-12-06 2014-01-09 フォリカ，インコーポレイテッド 禿頭症を治療するため、および毛髪の成長を促進するための方法
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11512289B2 (en) 2015-02-18 2022-11-29 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US10857181B2 (en) 2015-04-21 2020-12-08 Enlivex Therapeutics Ltd Therapeutic pooled blood apoptotic cell preparations and uses thereof
CA3014885A1 (en) 2016-02-18 2017-08-24 Enlivex Therapeutics Ltd. Combination immune therapy and cytokine control therapy for cancer treatment
US11427538B2 (en) * 2017-04-28 2022-08-30 Kyoto University Organic tellurium compound, method for producing same, living radical polymerization initiator, method for producing vinyl polymer, and vinyl polymer
KR20250151619A (ko) 2017-06-30 2025-10-21 더 리전트 오브 더 유니버시티 오브 캘리포니아 모발 성장을 조절하기 위한 조성물 및 방법
EA202090855A1 (ru) * 2017-09-29 2020-06-26 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Композиции и способы модуляции роста волос
JP2021042161A (ja) * 2019-09-11 2021-03-18 国立大学法人東海国立大学機構 脱毛剤、脱毛モデル動物及び白髪モデル動物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3369550A (en) 1967-02-17 1968-02-20 Thomas A. Armao Cryogenic clamps
GB1427415A (en) 1973-09-21 1976-03-10 Armao T A Cryosurgical instruments
US4139619A (en) * 1976-05-24 1979-02-13 The Upjohn Company 6-Amino-4-(substituted amino)-1,2-dihydro-1-hydroxy-2-iminopyrimidine, topical compositions and process for hair growth
US5102908A (en) 1985-03-15 1992-04-07 Michael Albeck Method of treating Acquired Immunedeficiency Syndrome (AIDS) using organic tellurium and selenium derivatives
US4761490A (en) 1985-03-15 1988-08-02 Bar-Ilan University Organic derivatives of tellurium and selenium and their use to stimulate cytokine production
US4962207A (en) * 1985-09-30 1990-10-09 Bar-Ilan University Organic derivatives of tellurium and selenium
US5093135A (en) * 1985-09-30 1992-03-03 Michael Albeck Compounds for the induction of in vivo and in vitro production of cytokines
US4752614A (en) 1985-09-30 1988-06-21 Bar-Ilan University Pharmaceutical compositions of tellerium and selenium compounds for the induction of in vivo and in vitro production of cytokines
US4764461A (en) * 1985-09-30 1988-08-16 Bar-Ilan University Tellurium and selenium compounds for the induction of in vivo and in vitro production of cytokines
US4929739A (en) * 1988-03-24 1990-05-29 Bar-Ilan University Complexes of tellurium and selenium derivatives
DE4007473A1 (de) 1990-03-09 1991-09-12 Tomsk G Med I Kryoskalpell
US5271925A (en) 1990-03-09 1993-12-21 Benjamin Sredni Method for protecting against the effects of radiation which is based on the administration of a selenium or tellurium based compound
US5213899A (en) * 1990-12-17 1993-05-25 General Electric Company Room temperature vulcanizable silicone compositions
US5262149A (en) 1992-08-13 1993-11-16 Benjamin Sredni Method of treating or preventing alopecia
SK280278B6 (sk) 1994-09-01 1999-10-08 Pharmacia + Upjohn Company Sterilná vodná farmaceutická kompozícia na parente
US5576347A (en) * 1994-11-14 1996-11-19 Sredni; Benjamin Method of treating gastric ulcers
US5654328A (en) * 1994-12-15 1997-08-05 Sredni; Benjamin Method and composition for reducing tumor development with a combination of platinum and tellurium or selenium compounds
WO1996018401A1 (en) * 1994-12-15 1996-06-20 Baker Norton Pharmaceuticals, Inc. Method and composition for reducing tumor development with a combination of a taxane compound and a tellurium and/or selenium compound
BRPI9909660B8 (pt) * 1998-03-19 2021-05-25 Vertex Pharma compostos inibidores de caspases, composição farmacêutica e uso de ditos compostos
US6428534B1 (en) * 1999-02-24 2002-08-06 Cryovascular Systems, Inc. Cryogenic angioplasty catheter
AU4213500A (en) * 1999-04-09 2000-11-14 Cytovia, Inc. Caspase inhibitors and the use thereof
CA2380935A1 (en) * 2000-05-23 2001-11-29 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
AU2001275279B2 (en) * 2000-06-07 2007-01-04 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
WO2001098325A1 (en) 2000-06-19 2001-12-27 University Of Southern California Methods for treating and preventing alopecia
US6747008B1 (en) * 2000-06-19 2004-06-08 University Of Southern California Methods for treating and preventing alopecia
BR0115546A (pt) * 2000-11-21 2003-09-16 Vertex Pharma Inibidores de imidazol e de benzimidazol caspase e usos dos mesmos
US20030148970A1 (en) 2001-01-12 2003-08-07 Besterman Jeffrey M. Methods for specifically inhibiting histone deacetylase-4
JP4428926B2 (ja) * 2001-05-23 2010-03-10 バーテックス ファーマシューティカルズ インコーポレイテッド カスパーゼインヒビターおよびそれらの使用
US6472381B1 (en) * 2001-10-12 2002-10-29 Biomas Inc. Method of treating psoriasis
IL146694A (en) * 2001-11-22 2010-12-30 Biomas Ltd Use of an aqueous solution containing a biologically active complex of tellurium dioxide for manufacturing a medicament
PL374598A1 (en) * 2002-06-28 2005-10-31 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
CN100366612C (zh) * 2002-12-20 2008-02-06 沃泰克斯药物股份有限公司 4-氧代-3-(1-氧代-1h-异喹啉-2-基乙酰氨基)-戊酸酯和酰胺衍生物及其作为天冬氨酸特异性半胱氨酸蛋白酶抑制剂的用途
CA2550459C (en) * 2003-12-18 2009-12-15 Biomas, Ltd. Tellurium derivatives for prevention and treatment of neurodegenerative processes
WO2006030441A2 (en) 2004-09-15 2006-03-23 Itamar Medical Ltd. Measuring blood flow and venous capacitance
US20080260770A1 (en) 2004-09-17 2008-10-23 Biomas Ltd. Use of Tellurium Compounds as Adjuvants
CA2580643C (en) 2004-09-17 2018-06-12 Biomas, Ltd. Use of tellurium compounds for inhibition of interleukin-converting enzyme

Also Published As

Publication number Publication date
EP1802292A4 (en) 2008-02-13
WO2006030438A2 (en) 2006-03-23
EP1796660A2 (en) 2007-06-20
US20100081623A1 (en) 2010-04-01
US20100233294A1 (en) 2010-09-16
US8623908B2 (en) 2014-01-07
US20080015175A1 (en) 2008-01-17
AU2005283719A1 (en) 2006-03-23
CA2580643C (en) 2018-06-12
JP2008513439A (ja) 2008-05-01
EP1796660A4 (en) 2008-01-16
CA2580643A1 (en) 2006-03-23
US20090269418A1 (en) 2009-10-29
CA2580804A1 (en) 2006-03-23
US20070298124A1 (en) 2007-12-27
EP1791535B1 (en) 2008-07-30
EP1796660B1 (en) 2016-11-23
WO2006030439A3 (en) 2007-05-18
CA2580642A1 (en) 2006-03-23
DE602005008622D1 (de) 2008-09-11
WO2006030438A3 (en) 2006-05-04
ATE402709T1 (de) 2008-08-15
HK1103355A1 (en) 2007-12-21
US7709524B2 (en) 2010-05-04
WO2006030437A3 (en) 2006-06-22
US7652065B2 (en) 2010-01-26
ES2312012T3 (es) 2009-02-16
EP1802292A2 (en) 2007-07-04
CA2580642C (en) 2014-09-02
WO2006030437A2 (en) 2006-03-23
WO2006030439A2 (en) 2006-03-23
EP1791535A2 (en) 2007-06-06
PT1796660T (pt) 2017-02-13

Similar Documents

Publication Publication Date Title
ES2614113T3 (es) Uso de tricloro (dioxietilen-O,O’) telurato de amonio (AS101) para la inhibición de la enzima convertidora de interleucina-1 beta
US12138311B2 (en) Topical tetracycline compositions
KR100962751B1 (ko) 면역 반응 변경제를 포함하는 제약 제제
KR20180095702A (ko) 모발 성장 조성물 및 방법
CN106659647B (zh) 含米诺地尔的毛发生长组合物
DE69823663T2 (de) Selbstemulgierbare formulierung enthaltend lipophile verbindungen
ES2633919T3 (es) Composición tópica
RU2000104856A (ru) Самоэмульгирующаяся композиция для липофильных соединений
ES2341379T3 (es) Uso de alopurinol para el tratamiento de eritrodisestesia palmoplantar.
ES2316312A1 (es) Composicion farmaceutica dermatologica para el tratamiento de patologias de inflamacion de la piel, tales como por ejemplo dermatitis, dermatitis atopica, vitiligo, alopecia areata, acne, psoriasis y prurito,y combinaciones de las mismas.
MX2011005410A (es) Formulacion farmaceutica que comprende diclofenaco y un ester de polioxialquileno de hidroxiacido graso.
Abdel-Bar et al. Evaluation of brain targeting and mucosal integrity of nasally administrated nanostructured carriers of a CNS active drug, clonazepam
WO2016104889A1 (en) Composition for a self-emulsifying drug delivery system comprising dutasteride
AR043106A2 (es) Formulaciones farmaceuticas para la administracion oral y topica y formas de dosis farmaceutica
CA2584124A1 (en) Flavonoid composition for treating oral diseases
JP2013515020A5 (enExample)
SG174612A1 (en) Stable pharmaceutical compositions of diclofenac
JPH0338525A (ja) コルチコステロイド含有外用クリーム製剤
US7625945B2 (en) Andrographolide and analogues as inhibitors of TNFα and IL-1β expression
KR20130015469A (ko) 개선된 제형 안정도를 갖는 워시오프 화장료 조성물
KR102670293B1 (ko) 풀베스트란트 제제 및 그의 사용 방법
BR9712020A (pt) Formula-{es para uso tÄpico
Ansari et al. Evaluation of antifungal activity of Olive oil based nanoemulsions
US8394424B2 (en) Topical phytotherapeutic compound for the treatment of herpes based on Uncaria tomentosa and extraction process for obtaining a vegetal extract from Uncaria tomentosa
ES2403380T3 (es) Formulación farmacéutica que comprende cetoprofeno y un éster de polioxialquileno de un hidroxiácido graso